Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. - Wikidata - awgldk - TriplyDB

Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction.

Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction.

http://www.wikidata.org/entity/Q30968626

about

Adult stem cells as a tool for kidney regeneration Impact of Timing following Acute Myocardial Infarction on Efficacy and Safety of Bone Marrow Stem Cells Therapy: A Network Meta-Analysis Critical Roles of Reactive Oxygen Species in Age-Related Impairment in Ischemia-Induced Neovascularization by Regulating Stem and Progenitor Cell Function Adipose tissue-derived stem cells as a therapeutic tool for cardiovascular disease Cardiac regeneration therapy: connections to cardiac physiology Stem cell therapy for incontinence: where are we now? What is the realistic potential?Epigenetic mechanisms underlying cardiac degeneration and regeneration Enhancing retention and efficacy of cardiosphere-derived cells administered after myocardial infarction using a hyaluronan-gelatin hydrogel Current stem cell delivery methods for myocardial repair Regenerative principles enrich cardiac rehabilitation practice Generation of Functional Cardiomyocytes from Efficiently Generated Human iPSCs and a Novel Method of Measuring Contractility Bioluminescent imaging of genetically selected induced pluripotent stem cell-derived cardiomyocytes after transplantation into infarcted heart of syngeneic recipients Cardiac Progenitor Cells in Myocardial Infarction Wound Healing: A Critical Review The stuttering progress of cell therapy for heart disease Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial Fifteen years of bone marrow mononuclear cell therapy in acute myocardial infarction Detection of intramyocardially injected DiR-labeled mesenchymal stem cells by optical and optoacoustic tomography Cell therapy for cardiac repair--lessons from clinical trials.Laser-supported CD133+ cell therapy in patients with ischemic cardiomyopathy: initial results from a prospective phase I multicenter trial.Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy.Implementation of cardovascular cell therapy network trials: challenges, innovation and lessons learned from experience in the CCTRN Heterogeneity in SDF-1 expression defines the vasculogenic potential of adult cardiac progenitor cells.Additive value of adult bone-marrow-derived cell transplantation to conventional revascularization in chronic ischemic heart disease: a systemic review and meta-analysis.Long-term effects of autologous bone marrow stem cell treatment in acute myocardial infarction: factors that may influence outcomes.Blood vessel repair and regeneration in the ischaemic heart Human endothelial stem/progenitor cells, angiogenic factors and vascular repair.Cardiac muscle regeneration: lessons from development.Strategies for cardiac regeneration and repair.eNOS overexpressing bone marrow cells are safe and effective in a porcine model of myocardial regeneration following acute myocardial infarction.Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges Cardiomyocyte protection by GATA-4 gene engineered mesenchymal stem cells is partially mediated by translocation of miR-221 in microvesicles.The effect of bone marrow mononuclear stem cell therapy on left ventricular function and myocardial perfusion.Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival.Cardiac cell therapy: where we've been, where we are, and where we should be headed.Circulating stem cell vary with NYHA stage in heart failure patients.Mixed serum-deprived and normal adipose-derived mesenchymal stem cells against acute lung ischemia-reperfusion injury in rats.Characterization of bone marrow mononuclear cells on biomaterials for bone tissue engineering in vitro.Acidic Fibroblast Growth Factor Promotes Endothelial Progenitor Cells Function via Akt/FOXO3a Pathway.Myocardial restoration: is it the cell or the architecture or both?A long road for stem cells to cure sick hearts: update on recent clinical trials.

P2860

Q26770750-7DB2E666-CE81-4982-9B74-0B0EF46CF9EC Q26771257-87133DE7-38EE-469B-B654-75C8DACCCB77 Q26772290-D248592F-EAA2-4C65-8484-07162DEC5A40 Q26795749-BB86A925-894C-4569-8D97-018CB3C3EC84 Q26822619-A09131C4-6A3B-4A28-88D1-219E198260FC Q26827498-62DF0CE7-4504-45E9-8571-5E4CC294BD9A Q26853220-6B9AE99C-45C9-49F9-BA5D-D9A2E93F8549 Q27002606-BB91EAC6-353A-4B27-893B-48CC2C273747 Q27004753-8A9C9216-BFF5-4573-B93E-E98640C1173F Q27022906-F410D9B3-8359-47C3-BF38-D013A9490EE0 Q27301480-463F72A1-9D50-417D-A5AC-75520316E8E7 Q27347592-67D4535B-2677-41D2-B08F-7A6B0375393E Q27686825-6A71375A-7F5E-4822-B297-EE8E9504831F Q28247457-590F3F23-8C8E-4CFF-922B-E1D9C1A9E99D Q29620043-2E3FD945-7196-409B-8262-BA9912651B0F Q29994502-D6F844A9-ABF2-4031-ABC3-A0E9CDA24726 Q30355871-D8238C6D-8F3C-44BD-8490-4614E0A1AB16 Q30359782-6D456586-C0C6-4C41-99F7-82EB35D863B1 Q33855567-2EB03B12-0125-4BE5-81A3-D3B3C315A2CC Q33919886-A4E335F2-29A7-4149-8168-EE21A743859B Q33981146-FBB2D313-CF87-48DD-B6CD-588065368E20 Q34009778-193D70D8-5492-4499-859C-675A961917C6 Q34043802-956B2C09-4CD7-4195-9DC6-FF6D6964E4A3 Q34288961-4A31AF4D-03B0-4A44-AE34-6B2812207BCF Q34304413-7564821E-1DFF-468E-AC5A-BF9D9E6528BA Q34333348-13A6CD99-E6E1-48A6-98DD-0BAA78A5BB74 Q34588417-1EEEA359-4F88-48DD-BE98-1D96637FA685 Q34795299-38F458DB-CF26-4754-AFEF-756FE8591B52 Q34803600-5D9318B2-29A7-4ED3-8799-FA30C5C36045 Q34981433-D7ADC4FC-CAF7-482A-985C-F94C965970E3 Q34981722-DE50A739-023D-4FBE-8E6E-19A7C8931711 Q35079018-EB02AF55-9DE6-4F88-9696-C38EB9309053 Q35102931-A8BFE5DE-7E05-4416-893B-7D0499F30EE4 Q35144550-0420F13F-B373-4114-B725-A44DF0BE135F Q35216154-F7450935-0003-4C89-8290-E83ACF5EF272 Q35440052-69D0FF15-E726-465C-B43C-E1C51A5AB434 Q35584996-57D51116-C392-4C4B-BC62-D1F6DAA8ACB7 Q35659739-494A15DC-B2B7-4F60-8E40-FEB2A798AA3B Q35778889-977C25C5-2B5D-48BB-A27E-AB95C3BA7DCE Q35794808-EE423A00-8617-4A5F-A2B9-2C72EA5624C1

P2860

Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction.

http://www.wikidata.org/entity/Q30968626

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Clinical outcome 2 years after ...... n acute myocardial infarction.

@ast

Clinical outcome 2 years after ...... n acute myocardial infarction.

@en

type

label

Clinical outcome 2 years after ...... n acute myocardial infarction.

@ast

Clinical outcome 2 years after ...... n acute myocardial infarction.

@en

prefLabel

Clinical outcome 2 years after ...... n acute myocardial infarction.

@ast

Clinical outcome 2 years after ...... n acute myocardial infarction.

@en

P1433

Q30968626-93D3448B-A540-47B7-810C-3FB4C9ADAD64

P1476

Q30968626-D43B1C49-BFDF-4A37-81AB-F35D0C07687D

P2093

Q30968626-03E65338-7F3F-4335-BAB2-4154D3FBEF8B

Q30968626-08963D76-6154-471D-B916-5C7D3E03F169

Q30968626-2683650C-181B-4426-B159-4433014B2464

Q30968626-310235DC-21A5-4EC8-A4FF-3D0B0E23D073

Q30968626-471D7657-CBF5-4A9E-A710-BBFDA42E9048

Q30968626-51E1FE82-3AE1-4403-BAD7-D55C4944A776

Q30968626-72383763-746F-4EE8-9F9F-859306035435

Q30968626-734D2524-DE42-405B-BD18-11B6B94C9C91

Q30968626-81BBB375-639D-48D8-84E9-78957B8CB0C2

Q30968626-822EE585-50B2-4F19-B7F8-6002180143AA

P304

Q30968626-E6541880-CE64-49D9-B3B5-5574947CA96E

P31

Q30968626-0056DA56-3BAF-45E9-A252-C6FF30C0CD18

P356

Q30968626-F6F15C62-9DD5-43BE-BB13-1C68F03317E6

P433

Q30968626-AA065D67-FAFF-43BD-AEAA-04E9E39A5699

P478

Q30968626-46D00469-0592-477E-8275-6467AD689915

P50

Q30968626-0ACC4A6C-844B-4F66-9F4C-76AAF127D125

Q30968626-77A96A4A-775A-4245-B09B-72EDCB108989

Q30968626-A9443970-68B6-41DF-9A23-343E3252AF69

Q30968626-D4DB792E-051F-48DB-8FE9-3B3540ACB138

P577

Q30968626-8D73F025-4F1F-4E77-A546-2804E9A1FD46

P698

Q30968626-8DCA0526-C9EA-4D41-B060-C4E9F1269E49

P921

Q30968626-2D43F426-29C9-472D-80B7-B05E30435DCF

Q30968626-AA10E217-49B5-4173-B3D5-EFFBA12C3589

P356

CIRCHEARTFAILURE.108.843243

P1433

Circulation: Heart Failure

P1476

Clinical outcome 2 years after ...... n acute myocardial infarction.

@en

P2093

Albrecht Elsässer

http://www.w3.org/2001/XMLSchema#string

Christian W Hamm

http://www.w3.org/2001/XMLSchema#string

Detlef G Mathey

http://www.w3.org/2001/XMLSchema#string

Harald Tillmanns

http://www.w3.org/2001/XMLSchema#string

Jiangtao Yu

http://www.w3.org/2001/XMLSchema#string

REPAIR-AMI Investigators

http://www.w3.org/2001/XMLSchema#string

Rainer Hambrecht

http://www.w3.org/2001/XMLSchema#string

Roberto Corti

http://www.w3.org/2001/XMLSchema#string

Sandra Erbs

http://www.w3.org/2001/XMLSchema#string

Thorsten Dill

http://www.w3.org/2001/XMLSchema#string

P304

89-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCHEARTFAILURE.108.843243

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Stefanie Dimmeler

P577

2009-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19996415

http://www.w3.org/2001/XMLSchema#string

P921